Armata Pharmaceuticals Inc
$ 12.92
-4.51%
24 Apr - close price
- Market Cap 473,295,000 USD
- Current Price $ 12.92
- High / Low $ 13.60 / 12.87
- Stock P/E N/A
- Book Value -6.00
- EPS -4.80
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -34.39 %
- 52 Week High 14.98
- 52 Week Low 1.17
About
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment of antibiotic-resistant infections worldwide. The company is headquartered in Marina del Rey, California.
Analyst Target Price
$17.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-19 | 2025-11-12 | 2025-08-12 | 2025-05-05 | 2025-03-19 | 2024-11-12 | 2024-08-13 | 2024-05-07 | 2024-03-21 | 2023-11-14 | 2023-08-14 | 2023-05-11 |
| Reported EPS | -0.5112 | -0.74 | -0.45 | -0.1973 | -0.2317 | -0.15 | 0.25 | -0.69 | -0.55 | -0.75 | -0.1 | -0.4 |
| Estimated EPS | -0.19 | -0.5 | -0.39 | -0.38 | -0.35 | -0.28 | -0.44 | -0.31 | -0.35 | -0.31 | -0.37 | -0.32 |
| Surprise | -0.3212 | -0.24 | -0.06 | 0.1827 | 0.1183 | 0.13 | 0.69 | -0.38 | -0.2 | -0.44 | 0.27 | -0.08 |
| Surprise Percentage | -169.0526% | -48% | -15.3846% | 48.0789% | 33.8% | 46.4286% | 156.8182% | -122.5806% | -57.1429% | -141.9355% | 72.973% | -25% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARMP
2026-04-24 21:09:11
This article details the performance of 12 health care stocks during Friday's after-market trading session, highlighting both gainers and losers. Intellia Therapeutics, Compass Therapeutics, and CDT Equity were among the top risers, while Armata Pharmaceuticals, iTonic Holdings, and Cosmos Health experienced significant declines. The report provides market capitalization and percentage changes for each mentioned stock.
2026-04-23 00:39:00
The article states that Armata Pharmaceuticals (ARMP) has seen its price target increased by 16.67%, raising it to 17.85. No other information about the company, the analyst, or the reasons for the increase is provided in this brief snippet.
2026-04-16 13:09:04
This article reports that the price target for Armata Pharmaceuticals (ARMP) has been increased by 16.67% to $17.85. The information is concise, indicating a positive change in the financial outlook for the company.
2026-04-16 04:39:26
Armata Pharmaceuticals (ARMP) shares fell 6.4% to $12.06 on Wednesday with lower-than-average trading volume, despite generally positive analyst ratings and the stock trading above its 50-day and 200-day moving averages. The clinical-stage biotech company, which develops bacteriophage therapies, reported a significant quarterly loss and is anticipated to post a yearly EPS of -$0.95. Institutional ownership stands at approximately 3.6%.
2026-04-08 00:08:57
Armata Pharmaceuticals has scheduled its 2026 annual meeting of stockholders for June 11, 2026, at 8:30 a.m. Pacific Time. Stockholders of record as of April 17, 2026, will be eligible to vote, and the deadline for stockholder proposals and director nominations is April 12, 2026. An analyst last rated ARMP as a Hold with a $8.50 price target, and TipRanks' AI Analyst, Spark, also rates it as Neutral due to weak financial performance despite positive corporate events.
2026-04-03 07:39:56
Armata Pharmaceuticals (NYSE American: ARMP) has announced its 2026 annual meeting of stockholders will take place on June 11, 2026, at 8:30 a.m. Pacific Time at the company's Los Angeles offices. Stockholders of record as of April 17, 2026, are eligible to vote, and the deadline for stockholder proposals and director nominations is April 12, 2026, at 5:00 p.m. Pacific Time. Separately, the company reported fourth-quarter earnings below analyst expectations, with an adjusted EPS of -$3.42 against a -$0.19 estimate and revenue of $1.1 million below the anticipated $1.48 million.
